Expression and Clinical Relevance of Serum LncRNA NEAT1 and microRNA-31 in Patients with Advanced Lung Cancer and Pulmonary Infection.

Background: Lung cancer remains one of the leading causes of cancer-related mortality worldwide, with a substantial proportion of patients suffering from concurrent pulmonary infections. Despite advances in treatment modalities, the early diagnosis of lung cancer complicated by pulmonary infection remains challenging, often resulting in delayed intervention and poorer prognosis. Objective: This study aimed to investigate the expression and significance of serum long non-coding RNA (lncRNA) NEAT1 and microRNA-31 in patients with advanced lung cancer complicated by pulmonary infection. Methods: A total of 48 patients diagnosed with lung cancer complicated by pulmonary infection and admitted to the hospital between January 2021 and December 2021 constituted the experimental group, while 48 healthy volunteers recruited during the same period served as the healthy control group. The expression levels of NEAT1 and microRNA-31 in plasma samples obtained from peripheral blood were measured using quantitative real-time polymerase chain reaction (qRT-PCR), and their differential expression in plasma was compared between the two groups. Results: Significantly elevated levels of serum lncRNA NEAT1 and microRNA-31 were observed in the experimental group compared to the healthy control group. Furthermore, the expression levels of NEAT1 and microRNA-31 showed correlations with patient age and tumor size. Notably, the expression of NEAT1 exhibited no significant association with smoking status, whereas microRNA-31 expression displayed a significant relationship with smoking. Conclusions: Our findings demonstrate that lncRNA NEAT1 and microRNA-31 are markedly upregulated in the plasma of patients with advanced lung cancer complicated by pulmonary infection. These molecules hold promise as potential diagnostic markers for advanced lung cancer complicated by pulmonary infection and may provide early auxiliary diagnostic value for lung cancer.

Naringenin ameliorates atopic dermatitis by inhibiting inflammation and enhancing immunity through the JAK2/STAT3 pathway.

OBJECTIVE: Atopic dermatitis (AD) is an inflammatory skin disease. Naringenin (Nar) possesses an anti-inflammatory property. This paper attempts to discuss the functional mechanism of Nar in AD mice through the Janus kinase 2 (JAK2)/signal transducer and activation of transcription 3 (STAT3) pathway. METHODS: Mouse models of DNFB-induced AD were established and treated with Nar, followed by intraperitoneal injection with the JAK2/STAT3 pathway activator Coumermycin A1. Dermatitis severity was scored and the thickness of right ear was measured. The pathological changes in dorsal skin tissues were observed by HE staining. The number of infiltrated mast cells and eosinophilic granulocytes was counted by TB staining. The serum IgE level and levels of TNF-α, IL-6, IFN-γ, IL-12, and IL-5 in dorsal skin tissues were measured by ELISA. The levels of p-JAK2, JAK2, p-STAT3, and STAT3 were determined by Western blot. RESULTS: Nar decreased dermatitis scores and right ear thickness, alleviated skin lesions, and reduced the number of infiltrated mast cells and eosinophilic granulocytes in AD mice. The serum IgE level and levels of TNF-α, IL-6, IFN-γ, IL-12, and IL-5 in dorsal skin tissues of AD mice were diminished after Nar treatment in a dose-dependent manner. Nar inhibited the activation of the JAK2/STAT3 pathway. The activation of the JAK2/STAT3 pathway partially nullified the therapeutic function of Nar on AD mice. CONCLUSION: Nar protects mice from AD by inhibiting inflammation and promoting immune responses through the inhibition of the JAK2/STAT3 pathway.

lncRNA NEF inhibits glioma by downregulating TGF-ß1.

NEF is a tumor suppressing long non-coding (lnc)RNA in hepatocellular carcinoma. Based on current literature, the involvement of NEF in other human diseases is still unknown. The current study aimed to investigate the potential involvement of NEF in glioma, which is a type of rare, but aggressive malignancy. It was determined that NEF expression was downregulated in tumor tissues compared with adjacent heathy tissues. A low blood NEF level in patients with glioma effectively distinguished patients from healthy controls who had high blood NEF levels. Blood NEF levels were significantly correlation with distant tumor metastasis, but not tumor growth. Blood NEF levels were negatively correlated with blood transforming growth factor (TGF)-ß1 levels in patients with distant tumor metastasis, but not in patients with non-metastatic glioma and healthy controls. NEF overexpression inhibited cancer cell migration and invasion. In addition, NEF overexpression downregulated TGF-ß1 expression. The authors of the current study concluded that lncRNA NEF may inhibit glioma cell migration and invasion by downregulating TGF-ß1.